Raymond James & Associates Dexcom Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Dexcom Inc stock. As of the latest transaction made, Raymond James & Associates holds 1,247,013 shares of DXCM stock, worth $90.1 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

1,247,013

Previous 1,082,973 15.15%

Holding current value

$90.1 Million

Previous $123 Million 31.94%

% of portfolio

0.05%

Previous 0.08%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$64.0 - $116.06 $10.5 Million - $19 Million	164,040 Added 15.15%	1,247,013 $83.6 Million
Q2 2024 Jul 19, 2024	BUY	$110.31 - $140.45 $5.66 Million - $7.2 Million	51,273 Added 4.97%	1,082,973 $123 Million
Q1 2024 Apr 22, 2024	BUY	$114.22 - $140.1 $97.5 Million - $120 Million	853,743 Added 479.75%	1,031,700 $143 Million
Q4 2023 Jan 16, 2024	SELL	$75.49 - $124.16 $10.8 Million - $17.8 Million	-143,569 Reduced 44.65%	177,957 $22.1 Million
Q3 2023 Oct 24, 2023	SELL	$86.06 - $137.93 $2.72 Million - $4.36 Million	-31,612 Reduced 8.95%	321,526 $30 Million
Q2 2023 Jul 25, 2023	BUY	$112.47 - $130.98 $3.28 Million - $3.82 Million	29,200 Added 9.01%	353,138 $45.4 Million
Q1 2023 Apr 14, 2023	SELL	$104.0 - $122.92 $7.28 Million - $8.61 Million	-70,023 Reduced 17.77%	323,938 $37.6 Million
Q4 2022 Feb 08, 2023	SELL	$84.98 - $122.67 $4.92 Million - $7.11 Million	-57,938 Reduced 12.82%	393,961 $44.6 Million
Q3 2022 Oct 25, 2022	SELL	$76.35 - $94.18 $2.35 Million - $2.9 Million	-30,839 Reduced 6.39%	451,899 $36.4 Million
Q2 2022 Aug 12, 2022	BUY	$67.99 - $132.89 $25.1 Million - $49 Million	369,035 Added 324.56%	482,738 $36 Million
Q1 2022 May 11, 2022	BUY	$94.08 - $130.2 $588,376 - $814,270	6,254 Added 5.82%	113,703 $58.2 Million
Q4 2021 Feb 08, 2022	SELL	$129.87 - $162.82 $790,258 - $990,759	-6,085 Reduced 5.36%	107,449 $57.7 Million
Q3 2021 Nov 02, 2021	BUY	$106.71 - $143.18 $487,771 - $654,475	4,571 Added 4.2%	113,534 $62.1 Million
Q2 2021 Aug 11, 2021	BUY	$80.99 - $107.93 $4.92 Million - $6.56 Million	60,762 Added 126.06%	108,963 $46.5 Million
Q1 2021 May 14, 2021	SELL	$84.79 - $104.74 $215,875 - $266,668	-2,546 Reduced 5.02%	48,201 $17.3 Million
Q4 2020 Feb 12, 2021	SELL	$78.0 - $104.5 $2.53 Million - $3.39 Million	-32,395 Reduced 38.96%	50,747 $18.8 Million
Q3 2020 Nov 04, 2020	BUY	$95.51 - $112.95 $289,013 - $341,786	3,026 Added 3.78%	83,142 $34.3 Million
Q2 2020 Jul 28, 2020	BUY	$62.68 - $105.34 $141,406 - $237,647	2,256 Added 2.9%	80,116 $32.5 Million
Q1 2020 Apr 21, 2020	BUY	$47.79 - $75.63 $850,996 - $1.35 Million	17,807 Added 29.65%	77,860 $21 Million
Q4 2019 Feb 12, 2020	BUY	$36.62 - $57.29 $306,179 - $479,001	8,361 Added 16.17%	60,053 $13.1 Million
Q3 2019 Nov 07, 2019	BUY	$35.53 - $43.8 $500,475 - $616,966	14,086 Added 37.46%	51,692 $7.72 Million
Q2 2019 Aug 06, 2019	SELL	$27.84 - $38.92 $175,809 - $245,779	-6,315 Reduced 14.38%	37,606 $5.64 Million
Q1 2019 May 06, 2019	BUY	$28.07 - $38.18 $62,624 - $85,179	2,231 Added 5.35%	43,921 $5.23 Million
Q4 2018 Feb 11, 2019	BUY	$26.99 - $37.37 $303,448 - $420,150	11,243 Added 36.93%	41,690 $4.99 Million
Q3 2018 Nov 14, 2018	BUY	$23.35 - $36.72 $7,612 - $11,970	326 Added 1.08%	30,447 $4.36 Million
Q2 2018 Aug 14, 2018	BUY	$17.54 - $25.22 $29,589 - $42,546	1,687 Added 5.93%	30,121 $2.86 Million
Q1 2018 May 14, 2018	SELL	$13.06 - $18.54 $110,357 - $156,663	-8,450 Reduced 22.91%	28,434 $2.11 Million
Q4 2017 Feb 14, 2018	SELL	$11.12 - $15.38 $391,068 - $540,883	-35,168 Reduced 48.81%	36,884 $2.12 Million
Q3 2017 Nov 13, 2017	SELL	$11.36 - $18.98 $57,731 - $96,456	-5,082 Reduced 6.59%	72,052 $3.53 Million
Q2 2017 Aug 14, 2017	BUY	N/A	77,134	77,134 $5.64 Million

Others Institutions Holding DXCM

# of Institutions

1,071

Shares Held

362M

Call Options Held

4.11M

Put Options Held

3.61M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $27.9B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Dexcom Inc Transaction History